ADIL logo

Adial Pharmaceuticals (ADIL) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

27 July 2018

Indexes:

Not included

Description:

Adial Pharmaceuticals is a biopharmaceutical company focused on developing treatments for addiction and related disorders. Their main product, AD04, aims to help people with alcohol use disorder. The company uses innovative science to create effective therapies that improve patients' lives and promote recovery.

Events Calendar

Earnings

Next earnings date:

May 14, 2025

Recent quarterly earnings:

Nov 13, 2024

Recent annual earnings:

Apr 02, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Aug 07, 2023

Analyst ratings

Recent major analysts updates

14 Nov '24 Rodman & Renshaw
Buy
11 July '23 Brookline Capital
Buy
17 Aug '22 Maxim Group
Hold
13 Oct '21 Brookline Capital
Buy
29 June '21 Litchfield Hills
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Adial Pharmaceuticals (ADIL) Upgraded to Buy: Here's What You Should Know
Adial Pharmaceuticals (ADIL) Upgraded to Buy: Here's What You Should Know
Adial Pharmaceuticals (ADIL) Upgraded to Buy: Here's What You Should Know
ADIL
zacks.com25 November 2024

Adial Pharmaceuticals (ADIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
ADIL
prismmediawire.com23 October 2024

Glen Allen, VA, October 23, 2024 – PRISM MediaWire – Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
ADIL
globenewswire.com23 October 2024

GLEN ALLEN, Va., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York.

Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
ADIL
globenewswire.com19 September 2024

GLEN ALLEN, Va., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced database lock for the pharmacokinetics study of AD04, the Company's lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients (defined as < 10 drinks/drinking day).

Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
ADIL
globenewswire.com14 August 2024

GLEN ALLEN, Va., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the second quarter of 2024.

Why Is Adial Pharmaceuticals (ADIL) Up 61% Today?
Why Is Adial Pharmaceuticals (ADIL) Up 61% Today?
Why Is Adial Pharmaceuticals (ADIL) Up 61% Today?
ADIL
investorplace.com23 July 2024

Adial Pharmaceuticals (NASDAQ:ADIL) stock is rocketing higher on Tuesday after the clinical-stage biopharmaceutical company announced an update on its AD04 study. Adial Pharmaceuticals notes that AD04 is progressing to a second cohort in its pharmacokinetics study.

Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025
ADIL
investorplace.com05 June 2024

Making millions through the stock market is only possible in a few ways. Investors need one of these three things: Massive sums of capital to begin with Decades of time and more modest sums of capital More modest sums of capital and a combination of risk and luck We will be talking about the latter today: seven stocks you can buy for $2 that can 10X by 2025.

Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th
Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th
Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th
ADIL
globenewswire.com29 May 2024

GLEN ALLEN, Va., May 29, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in the Spring MicroCap Rodeo Conference that will be held on Thursday, June 6, 2024 in New York City.

Adial Pharmaceuticals posts promising update on alcohol disorder drug
Adial Pharmaceuticals posts promising update on alcohol disorder drug
Adial Pharmaceuticals posts promising update on alcohol disorder drug
ADIL
Invezz10 April 2024

Adial Pharmaceuticals Inc (NASDAQ: ADIL) saw a 60% increase in its stock today after announcing positive results for its alcohol disorder drug. The Virginia-based company, valued at $7.7 million, reported promising results for its AD04 drug in a clinical trial involving patients with Alcohol Use Disorder (AUD).

Why Is Adial Pharmaceuticals (ADIL) Stock Up 59% Today?
Why Is Adial Pharmaceuticals (ADIL) Stock Up 59% Today?
Why Is Adial Pharmaceuticals (ADIL) Stock Up 59% Today?
ADIL
InvestorPlace10 April 2024

Adial Pharmaceuticals (NASDAQ: ADIL ) stock is on the rise today after receiving favorable results from a peer review of its Alcohol Use Disorder ( AUD ) treatment. The focus of this peer review was on the Phase 3 clinical trial outcomes for AD04.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the primary business of Adial Pharmaceuticals?
  • What is the ticker symbol for Adial Pharmaceuticals?
  • Does Adial Pharmaceuticals pay dividends?
  • What sector is Adial Pharmaceuticals in?
  • What industry is Adial Pharmaceuticals in?
  • What country is Adial Pharmaceuticals based in?
  • When did Adial Pharmaceuticals go public?
  • Is Adial Pharmaceuticals in the S&P 500?
  • Is Adial Pharmaceuticals in the NASDAQ 100?
  • Is Adial Pharmaceuticals in the Dow Jones?
  • When was Adial Pharmaceuticals's last earnings report?
  • When does Adial Pharmaceuticals report earnings?
  • Should I buy Adial Pharmaceuticals stock now?

What is the primary business of Adial Pharmaceuticals?

Adial Pharmaceuticals is a biopharmaceutical company focused on developing treatments for addiction and related disorders. Their main product, AD04, aims to help people with alcohol use disorder. The company uses innovative science to create effective therapies that improve patients' lives and promote recovery.

What is the ticker symbol for Adial Pharmaceuticals?

The ticker symbol for Adial Pharmaceuticals is NASDAQ:ADIL

Does Adial Pharmaceuticals pay dividends?

No, Adial Pharmaceuticals does not pay dividends

What sector is Adial Pharmaceuticals in?

Adial Pharmaceuticals is in the Healthcare sector

What industry is Adial Pharmaceuticals in?

Adial Pharmaceuticals is in the Biotechnology industry

What country is Adial Pharmaceuticals based in?

Adial Pharmaceuticals is headquartered in United States

When did Adial Pharmaceuticals go public?

Adial Pharmaceuticals's initial public offering (IPO) was on 27 July 2018

Is Adial Pharmaceuticals in the S&P 500?

No, Adial Pharmaceuticals is not included in the S&P 500 index

Is Adial Pharmaceuticals in the NASDAQ 100?

No, Adial Pharmaceuticals is not included in the NASDAQ 100 index

Is Adial Pharmaceuticals in the Dow Jones?

No, Adial Pharmaceuticals is not included in the Dow Jones index

When was Adial Pharmaceuticals's last earnings report?

Adial Pharmaceuticals's most recent earnings report was on 13 November 2024

When does Adial Pharmaceuticals report earnings?

The next expected earnings date for Adial Pharmaceuticals is 14 May 2025

Should I buy Adial Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions